BioSpace News Archive

Genetown

Boston’s Vida Ventures Snags $600 Million for New Life Science Fund

Vida launched in April 2017 and already has over a $1 billion in funds. It has invested in 14 companies, and three have launched initial public offerings.

August 1, 2019

·

3 min read

·

Mark Terry

Drug Development

Novartis’ Kisqali Effective in Postmenopausal Women with Breast Cancer

Novartis announced that its Phase III MONALEESA-3 clinical trial of Kisqali (ribociclib) hit its key secondary endpoint, overall survival, in a pre-planned interim analysis.

August 1, 2019

·

3 min read

·

Mark Terry

BioCapital

Study: Patients’ Immune Reactions to Checkpoint Inhibitors May Reflect Better 5-Year Survival Rates

Researchers with Johns Hopkins Kimmel Cancer Center recently published research that followed 270 cancer patients treated with Bristol-Myers Squibb’s checkpoint inhibitor Opdivo (nivolumab). The research reported impressive improvements in five-year survival rates.

August 1, 2019

·

2 min read

·

Mark Terry

Genetown

Biopharma Q2 Reports: Sanofi, Pfizer, Charles River, Gilead and Merck

There were a number of major companies reporting their second-quarter financials for the year. Here’s a look at five of the bigger announcements this week.

August 1, 2019

·

4 min read

·

Mark Terry

Policy

UC-Berkeley Rekindles U.S. Patent Dispute with the Broad Institute over CRISPR

Although the lawsuits over who owns the rights to gene editing technique CRISPR seemed to be mostly settled in September 2018, a recent dispute between the University of California and the Cambridge, Massachusetts-based Broad Institute suggested the battles aren’t done yet.

August 1, 2019

·

3 min read

·

Mark Terry

Policy

New Antibody Drug to Potentially Treat Cancer

Singapore scientists and clinicians have discovered a promising use of antibodies to target a new cancer antigen, as an alternative for chemotherapy

August 1, 2019

·

5 min read

Business

Regenstrief/VA researcher awarded $21 million to study chronic low back pain management

Matthew J. Bair, M.D., M.S., a research scientist with the Regenstrief Institute and the U.S. Department of Veterans Affairs, will co-lead a $21 million national study to find the best approach to manage chronic low back pain.

August 1, 2019

·

3 min read

BioSpace Global Roundup, August 1

Companies from across the globe share business and pipeline updates.

August 1, 2019

·

2 min read

·

Ellen Bombela

Business

Exelixis Bolsters Pipeline in Deal with India’s Aurigene

Under the terms of the deal, Exelixis is paying Aurigene $10 million up front for exclusive options to license three existing programs. The two companies will then launch three drug discovery programs led by Aurigene on mutually agreed-upon targets.

August 1, 2019

·

3 min read

·

Mark Terry

BioForest

New Approach in CRISPR Shows Promise in Treating Blood Disorders

The researchers, led by Hans-Peter Kiem, used CRISPR to modify hematopoietic stem cells from nonhuman primates. They then introduced a naturally occurring mutation that increases the amount of fetal hemoglobin.

August 1, 2019

·

2 min read

·

Mark Terry